To evaluate the utility of serum biomarkers to predict the castration resistance of prostate cancer patients, a prospective study to examine the IL13Rα2 expression levels in tissue and serum samples of metastatic HNPC patients is needed. Here, IL13RA2 is linked to prostate cancer.